4 recruiting, 3 unknown, 2 completed. 9 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Recruiting 4, Unknown 3, Completed 2 |
| Phase 1 | 4 | Recruiting 2, Completed 1, Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Refractory Leukemia: new trials by email Literature Review of Refractory Leukemia trials Research Report on Refractory Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Revumenib and Mezigdomide in People With Leukemia Revumenib, Mezigdomide - Leukemia, Acute Leukemia | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 52 | 2026-01-16 | 2026-10-20 |
| Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) Roginolisib, Venetoclax, Rituximab - Leukemia, Relapsed Leukemia | Phase 1 / Phase 2 | Recruiting | Jennifer R. Brown, MD, PhD | 64 | 2025-03-19 | 2026-02-11 |
| Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm CD123 targeted CAR-NK cells - Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Phase 1 / Phase 2 | Completed | Chongqing Precision Biotech Co., Ltd | 5 | 2024-03-28 | 2026-08-05 |
| Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi Leukemia CALGE-VEN- RIC-conditioning - Refractory Leukemia | Phase 2 | Recruiting | Shanghai Jiao Tong University School of Medicine | 100 | 2023-02-01 | 2025-02-18 |
| Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia BCL2 Inhibitor plus IM2 regimen - T-lymphoblastic Lymphoma, Relapsed Disease | Phase 2 | Unknown | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 30 | 2023-01-10 | 2023-06-28 |
| Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML venetoclax combining chidamide and azacitidine (VCA) - Leukemia, Myeloid, Acute, Relapsed Adult AML | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 30 | 2022-01-12 | 2025-09-11 |
| Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia Allogeneic CD19 CAR-T cells - Relapse Leukemia, Refractory Leukemia | Phase 1 / Phase 2 | Unknown | Shenzhen University General Hospital | 20 | 2021-02-05 | 2021-12-20 |
| Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia Decitabine, mBU/CY and ATG, mBU/CY - Stem Cell Transplant Complications, Relapse Leukemia | Phase 2 / Phase 3 | Unknown | Peking University People's Hospital | 55 | 2018-12-01 | 2019-05-29 |
| Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML) Panobinostat/LBH589 - Refractory Leukemia, Acute Myelogenous Leukemia | Phase 2 | Completed | Novartis Pharmaceuticals | 59 | 2009-08-01 | 2017-02-23 |
Leukemia (9) · Leukemia, Myeloid, Acute (5) · Recurrence (2) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)
Hematologic Diseases (9) · Hemic and Lymphatic Diseases (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Leukemia, Myeloid (5) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Leukemia, Lymphoid (3) · Lymphatic Diseases (3) · Lymphoproliferative Disorders (3) · Disease Attributes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Chronic Disease (1) · Hematologic Neoplasms (1)
Azacitidine (1) · Decitabine (1) · Panobinostat (1) · Rituximab (1) · revumenib (1) · venetoclax (1)
Chongqing Precision Biotech Co., Ltd (1) · Jennifer R. Brown, MD, PhD (1) · Memorial Sloan Kettering Cancer Center (1) · Novartis Pharmaceuticals (1) · Peking University People's Hospital (1) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1) · Shanghai Jiao Tong University School of Medicine (1) · Shenzhen University General Hospital (1) · The First Affiliated Hospital of Xiamen University (1)
China (6) · United States (3) · Australia (1) · Belgium (1) · France (1) · Germany (1) · Italy (1) · Peru (1) · South Korea (1) · Spain (1) · Switzerland (1) · Turkey (Türkiye) (1) · United Kingdom (1)
Bing Xu (1) · Chun Wang (1) · Jennifer Brown, MD, PhD (1) · Jia Wei, M.D (1) · Kuo-Kai Chin, MD (1) · Li Yu, Dr (1) · Xianmin G Song (1) · Xiao-Jun Huang (1)
2008 (1)